Sirtuin Dysfunction Validation in Parkinson's Disease

V2, Crosslink

🧫

Sirtuin Dysfunction Validation in Parkinson's Disease

active

experiment Created: 2026-04-02T10:01:41 By: crosslink-v2 Quality: 67% ✓ SciDEX ID: experiment-exp-wiki-experiments-sirtuin-

🧫 Experiment Protocol Clinicalproposed

SUMMARY

# Sirtuin Dysfunction Validation in Parkinson's Disease ## Background and Rationale Parkinson's disease (PD) is characterized by progressive neurodegeneration with accumulating evidence implicating mitochondrial dysfunction and impaired protein quality control. The Sirtuin Dysfunction Hypothesis proposes that dysregulation of NAD+-dependent sirtuin deacetylases contributes to PD pathogenesis through compromised mitochondrial biogenesis, defective autophagy, and increased oxidative stress. This c

METHODOLOGY NOTES

Phase 1 (Months 1-12): Recruit 120 PD patients (Hoehn-Yahr stages I-III) and 80 age-matched controls. Collect fasting blood samples at baseline and 6 months. Isolate PBMCs using Ficoll gradient centrifugation. Measure SIRT1, SIRT2, SIRT3 activities using fluorometric deacetylase assays. Quantify NAD+/NADH ratios via enzymatic cycling assays. Assess mitochondrial function using Seahorse XF analyzer measuring oxygen consumption rates. Evaluate autophagy markers (LC3-II/I ratio, p62 levels) by Western blot. Perform plasma metabolomics focusing on NAD+ biosynthesis pathway. Clinical assessments include UPDRS-III, MoCA, and PDQ-39 quality of life scores. Phase 2 (Months 13-24): Randomize 80 PD patients to resveratrol (1000mg daily) or placebo for 24 weeks. Primary endpoint: change in UPDRS-III motor scores. Secondary endpoints include cognitive testing, biomarker changes, and safety monitoring. Blood sampling at weeks 0, 4, 12, and 24 for sirtuin activities and NAD+ levels. Statistical anal

▸Metadatasource: {'type': 'manual', 'source_name': 'wiki'

source	{'type': 'manual', 'source_name': 'wiki', 'extracted_by': 'backfill_v1', 'extraction_date': '2026-04-16T01:00:16.898113Z'}
summary	# Sirtuin Dysfunction Validation in Parkinson's Disease ## Background and Rationale Parkinson's disease (PD) is characterized by progressive neurodegeneration with accumulating evidence implicating mi
entities	{'genes': ['SIRT'], 'diseases': ["Parkinson's Disease"]}
model_system	human
_schema_version	1
experiment_type	clinical
primary_outcome	Validate Sirtuin Dysfunction Validation in Parkinson's Disease
methodology_notes	Phase 1 (Months 1-12): Recruit 120 PD patients (Hoehn-Yahr stages I-III) and 80 age-matched controls. Collect fasting blood samples at baseline and 6 months. Isolate PBMCs using Ficoll gradient centri
replication_status	single_study
extraction_metadata	{'backfill_at': '2026-04-16T01:00:16.898118', 'needs_review': True, 'extraction_notes': 'Backfilled from wiki source (no PMID available)', 'extraction_confidence': 0.4}

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

673

Outgoing

648

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Sirtuin Dysfunction Validation in Parkinson's Disease

derives from (16)

supports (5)

💬 Discussion